LTP·01learntopeptide
Longevity & bioregulatorsEvidence D3 cited

Acein

aka ACE inhibitory peptide · antihypertensive peptide

A research peptide that inhibits connective tissue growth factor (CCN2/CTGF), a key mediator of tissue fibrosis. Targets the fundamental fibrotic pathway involved in organ aging and disease.

Molecular wt
933.1g/mol
Formula
C43H68N10O13
Route
Subcutaneous injection
PubChem
122177132

Sequence

One-letter9 residues

PPTTTKFAA

Three-letter

H-Pro-Pro-Thr-Thr-Thr-Lys-Phe-Ala-Ala-OH

Read this before quoting the sequence
Synthetic nonapeptide identified by in-house bioinformatics; the sequence is stated verbatim in the primary paper's abstract and matches PubChem CID 122177132. Distinct from the unrelated plasma-derived peptides 'acein-1' and 'acein-2' (Nakagomi et al., FEBS Lett 1998/2000).
Source ↗

Mechanism of action

Acein inhibits CCN2 (connective tissue growth factor, also known as CTGF), a matricellular protein that drives fibrosis in multiple organs. CCN2 promotes extracellular matrix deposition, myofibroblast differentiation, and TGF-beta-mediated fibrotic signaling. By blocking CCN2, Acein reduces collagen overproduction, prevents fibrotic tissue remodeling, and may reverse established fibrosis in liver, kidney, lung, and cardiac tissue.

What the evidence actually shows

Grade D

Early-stage research compound. Preclinical studies show anti-fibrotic effects in animal models. No human clinical trials completed. CCN2 is a validated fibrosis target (pamrevlumab anti-CCN2 antibody is in clinical trials).

Regulatory status

Status
Not an approved drug in any jurisdiction identified. No registered human clinical trial found on ClinicalTrials.gov.
Clinical stage
Preclinical (rodent, C. elegans and in vitro only)
Source ↗

Dosing — what backs each figure

Acein has never been given to humans in a published study. It is a laboratory nonapeptide characterised by direct intra-striatal injection in rats and by micromolar exposure in cell culture; there is no systemic dose, no route of clinical administration, and no human safety data.

PreclinicalAnimal studies — not a human dose

  • Intra-striatal injection of the nonapeptide stimulated dopamine release and induced dopamine-like motor effects; the injected quantity is reported in the full text, not the abstract

    rat (behaviour); guinea pig and rat brain membranes (binding) · intra-striatal injection (direct CNS) · PMID 27027724

  • 1 micromolar applied to cells in UV-induced photoaging models in vitro, plus an in vivo skin model

    human skin cells in vitro; rodent skin in vivo · topical / in vitro application · PMID 41241016

Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.

No established human dose
No approved label or completed human trial establishes a dosing regimen for this compound. Anything presented as a standard protocol for it — anywhere — is someone's convention rather than a finding.

Handling and storage

No compound-specific stability data exists
No compound-specific stability study (lyophilised or reconstituted) was located in a primary/regulatory source during this verification pass. Only generic synthetic-peptide handling guidance exists for this compound; no specific temperatures or durations are recorded here rather than fabricating them. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

References (3)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
casNumber, storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent, regulatory.wada

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Longevity & bioregulators

Carnosine
A naturally occurring dipeptide (beta-alanine + histidine) with potent anti-glycation, antioxidant, and pH-buffering properties. Acts as an AGE inhibitor, preventing cross-linking of proteins that accelerates tissue aging.
Cortagen
Cortagen is a short synthetic bioregulator peptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target the adrenal cortex, supporting the regulation of cortisol production and adrenal gland function. Bioregulator peptides are based on the concept that short peptide sequences derived from or mimicking endogenous tissue-specific peptides can restore gene expression patterns in aging or damaged tissues. Cortagen is proposed to normalise adrenal cortex function by interacting with DNA and modulating transcription of genes involved in steroidogenesis. While the bioregulator concept has theoretical appeal, the evidence base consists primarily of preclinical studies and observational reports from Russian clinical practice.
Epitalon
A tetrapeptide researched for telomerase activation and potential influence on cellular ageing and circadian rhythms.